San Diego-primarily based Viking Therapeutics marked by itself as a significant competitor during the weight loss drug market place in February right after revealing promising data from a mid-phase trial of experimental drug VK2735, which prompt it rivaled—and outperformed—Novo and Lilly drugs when presented to be a weekly injection As well as